Eriksson A S, Knutsson E, Nergårdh A
Departments of Pediatrics and Clinical Neurophysiology, Karolinska Hospital, Stockholm, Sweden.
Epilepsia. 2001 Feb;42(2):230-6. doi: 10.1046/j.1528-1157.2001.37799.x.
In a double-blind crossover study with lamotrigine (LTG), we investigated a possible relationship between the clinical responses and changes of the amount of epileptiform activity in EEG.
Twelve patients, aged 4-21 years, with generalized drug-resistant epilepsy who had responded to LTG, completed the study. Twenty-four-hour video-EEGs were taken during control, placebo, and drug phases. The amounts of epileptiform discharges were estimated and compared with the clinical effects.
The duration of periods of repeated epileptiform discharges was significantly reduced during the LTG phase compared with the placebo phase (n = 12, p = 0.04). Ten patients showed a reduction of the amount of epileptiform discharges in the LTG phase by a mean of 81% (range, 17-100%). Periods of repeated epileptiform discharges with duration longer than 30 s were significantly reduced in length (p = 0.03) and number (p = 0.04) during the LTG phase compared with the placebo phase. Shorter periods of epileptiform discharges and the numbers of single epileptiform discharges were not affected. In five patients there was a seizure reduction (>/=50%) concomitant with the reduction of epileptiform discharges in the EEG. The behavior improved during LTG treatment in all patients. The patients became more alert, and their concentration and performance improved, according to their parents and the medical personnel.
LTG in dosages of 1-8 mg/kg body weight was found to depress relatively long episodes of interictal, repetitive, epileptiform activity in young patients with drug-resistant epilepsy, whereas short episodes were not affected. It depressed seizures in about half of the patients studied but gave improvements of behavior in all patients.
在一项使用拉莫三嗪（LTG）的双盲交叉研究中，我们调查了临床反应与脑电图中癫痫样活动量变化之间的可能关系。
12名年龄在4至21岁之间、患有全身性耐药性癫痫且对LTG有反应的患者完成了该研究。在对照、安慰剂和药物阶段进行了24小时视频脑电图检查。估计癫痫样放电的量并与临床效果进行比较。
与安慰剂阶段相比，LTG阶段反复癫痫样放电的持续时间显著缩短（n = 12，p = 0.04）。10名患者在LTG阶段癫痫样放电量平均减少了81%（范围为17 - 100%）。与安慰剂阶段相比，LTG阶段持续时间超过30秒的反复癫痫样放电在长度（p = 0.03）和数量（p = 0.04）上均显著减少。较短的癫痫样放电期和单个癫痫样放电的数量未受影响。5名患者癫痫发作减少（≥50%），同时脑电图中癫痫样放电减少。所有患者在LTG治疗期间行为均有改善。据其父母和医务人员称，患者变得更加警觉，注意力和表现均有所改善。
发现体重1 - 8 mg/kg剂量的LTG可抑制耐药性癫痫年轻患者相对较长时间的发作间期、重复性癫痫样活动，而短时间发作不受影响。它使约一半研究患者的癫痫发作得到抑制，但所有患者的行为均有改善。
